Shimon Slavin

Q: What Schools Are Affiliated With Shimon Slavin

Shimon Slavin is affiliated with the following schools: Hannover Medical School, Tel Aviv University, Stanford University

Shimon Slavin's AcademicInfluence.com Rankings

Shimon Slavin

Philosophy

#5576

World Rank

#8416

Historical Rank

Logic

#2833

World Rank

#3892

Historical Rank

philosophy Degrees

Shimon Slavin

Biology

#7467

World Rank

#10398

Historical Rank

Immunology

#405

World Rank

#420

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Shimon Slavin's Degrees

Doctorate Medicine University of California, San Francisco
PhD Immunology Stanford University

Why Is Shimon Slavin Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Shimon Slavin's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. (1998) (2131)
Defining the intensity of conditioning regimens: working definitions. (2009) (1315)
Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning (2002) (1143)
Gene therapy for immunodeficiency due to adenosine deaminase deficiency. (2009) (926)
Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. (2010) (880)
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. (2009) (446)
Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. (1996) (431)
Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) (2005) (428)
Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice: long-term survival of allogeneic bone marrow and skin grafts (1977) (389)
Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. (2008) (325)
Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. (2008) (311)
Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. (2002) (270)
Spontaneous murine B-cell leukaemia (1978) (255)
Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. (2007) (253)
Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. (1995) (233)
Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. (2016) (227)
Mini-allografts: ongoing trials in humans (2000) (226)
The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group (2010) (218)
Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database (2006) (215)
Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. (2003) (210)
Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal (2013) (200)
Transplantation tolerance in adult rats using total lymphoid irradiation: permanent survival of skin, heart, and marrow allografts (1978) (193)
Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): A proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases (2008) (192)
Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma (2000) (191)
MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1 (2013) (190)
Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? (2002) (189)
Transplantation of allogeneic bone marrow without graft-versus-host disease using total lymphoid irradiation (1978) (176)
Safety of retroviral gene marking with a truncated NGF receptor (2003) (168)
Cannabidiol lowers incidence of diabetes in non-obese diabetic mice (2006) (163)
T‐cell‐depleted allogeneic bone marrow transplantation for acute leukaemia using Campath‐1 antibodies and post‐transplant administration of donor's peripheral blood lymphocytes for prevention of relapse (1995) (162)
The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. (2004) (159)
Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. (2008) (157)
T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. (2000) (156)
Allograft Tolerance after Total Lymphoid Irradiation (TLI) (1979) (140)
The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. (2006) (138)
Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study (2007) (134)
Invasive fungal sinusitis in patients undergoing bone marrow transplantation. (1993) (134)
Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT). (2005) (134)
Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. (1993) (129)
Right atrial thrombi are related to indwelling central venous catheter position: insights into time course and possible mechanism of formation. (1998) (127)
The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD? (1990) (125)
Induction of resistance to diabetes in non-obese diabetic mice by targeting CD44 with a specific monoclonal antibody. (2000) (125)
In vivo therapy of a murine B cell tumor (BCL1) using antibody-ricin A chain immunotoxins (1982) (124)
Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? (2012) (121)
Long-term survival of skin allografts in mice treated with fractionated total lymphoid irradiation. (1976) (121)
Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). (1993) (118)
Cannabidiol arrests onset of autoimmune diabetes in NOD mice (2008) (117)
Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. (2006) (117)
Adoptive transfer of immunity to hepatitis B virus after T cell–depleted allogeneic bone marrow transplantation (1993) (115)
Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. (2000) (113)
Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation. (1993) (113)
Mesenchymal stromal cells lose their immunosuppressive potential after allotransplantation. (2008) (112)
MicroRNA-145 Is Downregulated in Glial Tumors and Regulates Glioma Cell Migration by Targeting Connective Tissue Growth Factor (2013) (111)
Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. (2001) (109)
Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation (2008) (108)
Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double-blind placebo-controlled trial. (1992) (101)
Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation. (1992) (98)
Amelioration of diabetes in nonobese diabetic mice with advanced disease by linomide-induced immunoregulation combined with Reg protein treatment. (1998) (97)
Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. (1996) (92)
A fludarabine-based protocol for bone marrow transplantation in Fanconi’s anemia (1997) (91)
Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide (1993) (90)
Stimulation of immune reconstitution by interleukin-7 after syngeneic bone marrow transplantation in mice. (1996) (89)
Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation. (1997) (88)
A controlled trial of recombinant human erythropoietin after bone marrow transplantation. (1994) (87)
Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia (1996) (85)
Fractionated Total Lymphoid Irradiation as Preparative Immunosuppression in High Risk Renal Transplantation: Clinical and Immunological Studies (1982) (85)
A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. (2010) (84)
Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen (2001) (84)
The potential use of adult stem cells for the treatment of multiple sclerosis and other neurodegenerative disorders (2008) (83)
Anti-tumor effects of allogeneic bone marrow transplantation in (NZB X NZW)F1 hybrids with spontaneous lymphosarcoma. (1984) (83)
Fibrin microbeads for isolating and growing bone marrow-derived progenitor cells capable of forming bone tissue. (2002) (82)
A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. (2007) (82)
Conversion of red bone marrow into yellow - Cause and mechanisms. (2007) (82)
Induction of allograft tolerance after total lymphoid irradiation (TLI): development of suppressor cells of the mixed leukocyte reaction (MLR). (1979) (78)
Novel telomerase-increasing compound in mouse brain delays the onset of amyotrophic lateral sclerosis (2012) (78)
Allogeneic cell therapy for a murine mammary carcinoma. (1998) (76)
Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: effect of halofuginone. (1996) (76)
Natural killer cell HLA-C epitopes and killer cell immunoglobulin-like receptors both influence outcome of mismatched unrelated donor bone marrow transplants. (2005) (75)
Induction of graft vs. tumor effect in a murine model of mammary adenocarcinoma (1997) (73)
Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. (2009) (72)
Salvage high-dose chemotherapy for children with extragonadal germ-cell tumours (2005) (70)
Nosocomial coagulase-negative staphylococcal infections in bone marrow transplantation recipients with central vein catheter. A 5-year prospective study. (1996) (69)
Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation. (2000) (68)
Characterization of a spontaneous murine B cell leukemia (BCL1). I. Cell surface expression of IgM, IgD, Ia, and FcR. (1979) (68)
Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2. (1994) (68)
Chronic-relapsing experimental autoimmune encephalomyelitis (CR-EAE): treatment and induction of tolerance, with high dose cyclophosphamide followed by syngeneic bone marrow transplantation (1992) (67)
The hematological etiology of osteoporosis. (2006) (67)
Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated (1992) (67)
Recombinant human superoxide dismutases: production and potential therapeutical uses. (1991) (65)
Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT. (1996) (65)
Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia. (2000) (63)
Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic bone marrow transplantation for beta-thalassemia major. (1998) (62)
Reconstruction of Cartilage, Bone, and Hematopoietic Microenvironment with Demineralized Bone Matrix and Bone Marrow Cells (2003) (60)
Low‐dose γ‐irradiation promotes survival of injured neurons in the central nervous system via homeostasis‐driven proliferation of T cells (2004) (60)
Neurologic manifestations in patients with mixed cryoglobulinemia (1974) (60)
Immunobiology of a Spontaneous Murine B Cell Leukemia (BCL1) (1979) (60)
Alloantigen persistence in induction and maintenance of transplantation tolerance (1987) (59)
Immunotherapy of cancer with alloreactive lymphocytes. (2001) (59)
Induction and mechanism of tolerance to bovine serum albumin in mice given total lymphoid irradiation (TLI). (1978) (58)
Total lymphoid irradiation. (1987) (58)
Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia. (2013) (58)
Maintenance of immune memory to the hepatitis B envelope protein following adoptive transfer of immunity in bone marrow transplant recipients (2000) (57)
TRANSMISSION OF BRUCELLOSIS BY BONE MARROW TRANSPLANTATION (1982) (57)
Donor lymphocyte infusion post-non-myeloablative allogeneic peripheral blood stem cell transplantation for chronic granulomatous disease (1999) (55)
Transplantation of allogeneic or xenogeneic bone marrow within the donor stromal microenvironment. (1999) (55)
Treatment of post-hematopoietic stem cell transplantation hemorrhagic cystitis with intravesicular sodium hyaluronate (2006) (54)
New strategies for bone marrow transplantation. (2000) (53)
A longitudinal follow-up of salivary secretion in bone marrow transplant patients. (1995) (52)
Antitumor effects of human recombinant interleukin-6 on acute myeloid leukemia in mice and in cell cultures. (1992) (52)
Fludarabine-based protocol for human umbilical cord blood transplantation in children with Fanconi anemia. (1999) (52)
Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. (2015) (52)
Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI) (1981) (52)
Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation. (2002) (52)
Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. (1992) (51)
Treatment of life-threatening autoimmune diseases with myeloablative doses of immunosuppressive agents: experimental background and rationale for ABMT. (1993) (51)
CD44 Involvement in Autoimmune Inflammations (2007) (51)
Total Lymphoid Irradiation Prevents Diabetes Mellitus in the Bio-Breeding/Worcester (BB/W) Rat (1984) (51)
Allogeneic cell-mediated immunotherapy for breast cancer after autologous stem cell transplantation: a clinical pilot study. (1998) (50)
Adoptive immunotherapy in conjunction with bone marrow transplantation--amplification of natural host defence mechanisms against cancer by recombinant IL-2. (1988) (50)
Suppression and elimination of BCL1 leukemia by allogeneic bone marrow transplantation. (1983) (50)
Immune response to polio vaccination in bone marrow transplant recipients. (1991) (50)
Suppression of cell-mediated immune responses after total lymphoid irradiation (TLI). I. Characterization of suppressor cells of the mixed lymphocyte reaction. (1984) (50)
Successful haematopoietic stem cell transplantation in 44 children from healthy siblings conceived after preimplantation HLA matching. (2014) (49)
Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders. (1991) (48)
Enhanced marrow recovery by short preincubation of marrow allografts with human recombinant interleukin-3 and granulocyte-macrophage colony-stimulating factor. (1992) (48)
Bone marrow transplantation using unrelated and family related donors: the impact of HLA-C disparity. (1996) (48)
Immunomodulation of autoimmunity in MRL/lpr mice with syngeneic bone marrow transplantation (SBMT) (1995) (48)
Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors. (2006) (48)
Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond--the Acute Leukemia Working Party of the European Cooperative Grou (2006) (48)
Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine‐based preparative regimen (2006) (48)
Permanent and specific transplantation tolerance induced by a nonmyeloablative treatment to a wide variety of allogeneic tissues: I. Induction of tolerance by a short course of total lymphoid irradiation and selective elimination of the donor-specific host lymphocytes. (1997) (47)
Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCε-dependent downregulation of AKT and XIAP expressions. (2011) (46)
Development of antibodies to hepatitis B virus surface antigen in bone marrow transplant recipient following treatment with peripheral blood lymphocytes from immunized donors (1994) (46)
Nonmyeloablative conditioning to induce bilateral tolerance after allogeneic bone marrow transplantation in mice. (1999) (45)
Preimplantation Factor (PIF*) reverses neuroinflammation while promoting neural repair in EAE model (2012) (45)
Osmotic behavior of normal and leukemic lymphocytes. (1975) (45)
Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma. (1999) (45)
Successful transplantation of haploidentically mismatched peripheral blood stem cells using CD133+-purified stem cells. (2005) (44)
Peliosis Hepatis following treatment with androgen-steroids in patients with bone marrow failure syndromes (2007) (44)
Preimplantation factor (PIF) analog prevents type I diabetes mellitus (TIDM) development by preserving pancreatic function in NOD mice (2011) (44)
Effect of KRN7000 on induced graft-vs-host disease. (2004) (43)
Interleukin-6 receptor-interleukin-6 fusion proteins with enhanced interleukin-6 type pleiotropic activities. (1997) (43)
New developments in bone marrow transplantation. (1991) (43)
The response of cord blood megakaryocyte progenitors to IL‐3, IL‐6 and aplastic canine serum varies with gestational age (1995) (43)
Transplantation of bone marrow in outbred dogs without graft-versus-host disease using total lymphoid irradiation. (1979) (41)
Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report (2005) (40)
CpG-induced myeloid CD11b+Gr-1+ cells efficiently suppress T cell-mediated immunoreactivity and graft-versus-host disease in a murine model of allogeneic cell therapy. (2008) (40)
Osteogenic growth peptide increases blood and bone marrow cellularity and enhances engraftment of bone marrow transplants in mice. (1996) (40)
Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases. (2005) (40)
Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL (2016) (40)
Cell Therapy With Preimmunized Effector Cells Mismatched for Minor Histocompatible Antigens in the Treatment of a Murine Mammary Carcinoma (2001) (40)
Intracranial haematomas following bone marrow transplantation (1994) (40)
Characterization of the spontaneous murine B cell leukemia (BCL1). III. Evidence for monoclonality by using an anti-idiotype antibody. (1979) (40)
Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy--from bench to patient bedside. (2004) (39)
Telomere Shortening Sensitizes Cancer Cells to Selected Cytotoxic Agents: In Vitro and In Vivo Studies and Putative Mechanisms (2010) (39)
ELEVATED INFLAMMATORY CYTOKINE LEVELS IN BONE MARROW GRAFT REJECTION (1995) (39)
Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation. (2006) (38)
Enhancement of GVL effect with rhIL-2 following BMT in a murine model for acute myeloid leukemia in SJL/J mice. (1995) (38)
Intracoronary administration of autologous bone marrow mononuclear cells after induction of short ischemia is safe and may improve hibernation and ischemia in patients with ischemic cardiomyopathy. (2005) (38)
Low molecular weight heparin for hickman catheter‐induced thrombosis in thrombocytopenic patients undergoing bone marrow transplantation (1992) (38)
Interstitial pneumonitis after total body irradiation: effect of partial lung shielding (1990) (38)
Prevention and treatment of graft-versus-host disease by down-regulation of anti-host reactivity with veto cells of host origin (1999) (38)
Effects of recombinant human granulocyte and granulocyte-macrophage colony-stimulating factors on neutrophil function following autologous bone marrow transplantation. (1991) (38)
Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody. (2008) (37)
Correction of enzyme deficiency in mice by allogeneic bone marrow transplantation with total lymphoid irradiation. (1980) (37)
Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients (2004) (37)
Induction of antitumor immunity by indomethacin (2000) (36)
Effects of CAMPATH-1 antibodies on the functional activity of monocytes and polymorphonuclear neutrophils. (1993) (36)
The pathology and homing of a transplantable murine B cell leukemia (BCL1). (1979) (36)
Clinical application of intrauterine bone marrow transplantation for treatment of genetic diseases--feasibility studies. (1992) (36)
Functional clonal deletion versus active suppression in transplantation tolerance induced by total-lymphoid irradiation. (1985) (35)
A retrospective review of the outcome after second or subsequent allogeneic transplantation. (2009) (35)
Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigen pulsed donor lymphocytes (2001) (35)
A partial characterization of suppressor cells in the spleens of mice conditioned with fractionated total lymphoid irradiation (TLI). (1983) (35)
Transplantation tolerance after total lymphoid irradiation. (1979) (35)
Inhibition of metastatic cell colonization in murine lungs and tumor‐induced morbidity by non‐peptidic Arg‐Gly‐Asp mimetics (1993) (34)
Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo. (2003) (34)
Repair of bone defect using bone marrow cells and demineralized bone matrix supplemented with polymeric materials. (2010) (34)
Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens. (1993) (34)
Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome (2007) (33)
Analysis of beta-globin mutations shows stable mixed chimerism in patients with thalassemia after bone marrow transplantation. (1995) (33)
Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disorders. (2001) (33)
Non-myeloablative stem cell transplantation for autoimmune diseases (2004) (33)
Heparanase upregulates Th2 cytokines, ameliorating experimental autoimmune encephalitis. (2010) (33)
Tolerance to donor-type skin in the recipient of a bone marrow allograft. Treatment of skin ulcers in chronic graft-versus-host disease with skin grafts from the bone marrow donor. (1985) (32)
Ultrastructural, cell membrane, and cytogenetic characteristics of B-cell leukemia, a murine model of chronic lymphocytic leukemia. (1981) (32)
PREVENTION OF GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA BY T-CELL DEPLETION INVITRO PRIOR TO TRANSPLANTATION (1985) (32)
Osteoporosis of hematologic etiology. (2007) (31)
The oxidative status of blood cells in a murine model of graft-versus-host disease (2007) (31)
Prevention of diabetes in nonobese diabetic mice by nonmyeloablative allogeneic bone marrow transplantation. (2004) (31)
Cancer immunotherapy with alloreactive lymphocytes. (2000) (31)
Effect of cyclosporine A and methylprednisolone on the graft-versus-leukemia effects across major histocompatibility barriers in mice following allogeneic bone marrow transplantation. (1990) (31)
Neuroprotection in multiple sclerosis (2006) (31)
Prediction by a modified mixed leukocyte reaction assay of graft-versus-host disease and graft rejection after allogeneic bone marrow transplantation. (1994) (30)
The antiangiogenic agent linomide inhibits the growth rate of von Hippel-Lindau paraganglioma xenografts to mice. (1999) (30)
Allogeneic Cell‐Mediated and Cytokine‐Activated Immunotherapy for Malignant Lymphoma at the Stage of Minimal Residual Disease After Autologous Stem Cell Transplantation (1998) (30)
Total Lymphoid Irradiation (1980) (29)
Transplantation tolerance across major histocompatibility barriers after total lymphoid irradiation. (1979) (28)
Prevention of diabetes mellitus in non-obese diabetic mice by Linomide, a novel immunomodulating drug (1994) (28)
New Developments in the Therapy of Acute Myelocytic Leukemia. (2000) (28)
ABO incompatibility is associated with increased non-relapse and GVHD related mortality in patients with malignancies treated with a reduced intensity regimen: a single center experience of 221 patients. (2008) (28)
Induction of Tolerance to Experimental Anti‐Phospholipid Syndrome (APS) by Syngeneic Bone Marrow Cell Transplantation (1995) (27)
Detection of minimal residual disease state in chronic myelogenous leukemia patients using fluorescence in situ hybridization. (1994) (27)
Allogeneic hematopoietic stem cell transplantation in the elderly. (2007) (27)
Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models. (2002) (27)
Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies. (1999) (27)
Successful immunization of autologous bone marrow transplantation recipients against hepatitis B virus by active vaccination. (1995) (27)
Total lymphoid irradiation and kidney transplantation: a clinical experience. (1981) (26)
Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes. (2006) (26)
Oxidative stress protection by novel telomerase activators in mesenchymal stem cells derived from healthy and diseased individuals. (2013) (26)
Intra‐arterial catheter directed therapy for severe graft‐versus‐host disease (2002) (26)
Effect of total lymphoid irradiation (TLI) on the primary and secondary antibody response to sheep red blood cells. (1979) (26)
T-cell depletion in allogeneic bone marrow transplantation: progress and problems. (1989) (26)
Transplantation of Islet Cells Across Major Histocompatibility Barriers After Total Lymphoid Irradiation and Infusion of Allogeneic Bone Marrow Cells (1982) (25)
Successful treatment of autoimmune disease in (NZB/NZW)F1 female mice by using fractionated total lymphoid irradiation. (1979) (25)
Effect of exogenous recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor on neutrophil function following allogeneic bone marrow transplantation. (1991) (25)
The number of infused CD34+ cells does not influence the incidence of GVHD or the outcome of allogeneic PBSC transplantation, using reduced-intensity conditioning and antithymocyte globulin (2010) (24)
Cytokine production in Linomide-treated nod mice and the potential role of a Th (1)/Th(2) shift on autoimmune and anti-inflammatory processes. (2002) (24)
Allogeneic cell therapy: the treatment of choice for all hematologic malignancies relapsing post BMT. (1996) (24)
Total lymphoid irradiation in refractory systemic lupus erythematosus. (1986) (24)
Functional clonal deletion versus suppressor cell-induced transplantation tolerance in chimeras prepared with a short course of total-lymphoid irradiation. (1986) (24)
Effect of indomethacin on tumorigenicity and immunity induction in a murine model of mammary carcinoma (1998) (24)
Immunotherapy of minimal residual disease in conjunction with autologous and allogeneic bone marrow transplantation (BMT). (1992) (23)
Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: Getting closer to a cure? (2002) (23)
Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to upregulate antitumor effects and downregulate antihost responses (2003) (23)
IL-2 activated cell-mediated immunotherapy: control of minimal residual disease in malignant disorders by allogeneic lymphocytes and IL-2. (1990) (23)
Selective CD4+ T-cell depletion does not prevent graft-versus-host disease. (1998) (23)
Treatment of X‐linked childhood cerebral adrenoleukodystrophy by the use of an allogeneic stem cell transplantation with reduced intensity conditioning regimen (2005) (22)
Linomide, a new treatment for autoimmune diseases: the potential in type 1 diabetes. (1993) (22)
Typhlitis occurring in autologous bone marrow transplantation. (1992) (22)
The role of the spleen in tumor growth kinetics of the murine B cell leukemia (BCL1). (1980) (22)
The use of recombinant cytokines for enhancing immunohematopoietic reconstitution following bone marrow transplantation. I. Effects of in vitro culturing with IL-3 and GM-CSF on human and mouse bone marrow cells purged with mafosfamide (ASTA-Z). (1989) (22)
Ex vivo expansion of megakaryocyte precursors by preincubation of marrow allografts with interleukin-3 and granulocyte-macrophage colony-stimulating factor in vitro. (1995) (22)
Allogeneic cell therapy of severe beta thalassemia major by displacement of host stem cells in mixed chimera by donor blood lymphocytes (1997) (22)
Lymphocyte subpopulations in chronic active hepatitis: increase in lymphocytes forming stable E-rosettes. (1975) (22)
Early-onset Guillain-Barré syndrome associated with reactivation of Epstein-Barr virus infection after nonmyeloablative stem cell transplantation. (2004) (22)
Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man. (2003) (21)
New approaches for the prevention of rejection and graft-vs.-host disease in clinical bone marrow transplantation. (1986) (21)
Linomide, an immunomodulator that inhibits Th1 cytokine gene expression. (1996) (21)
The treatment of intractable rheumatoid arthritis with lymphoid irradiation. (1981) (21)
Effects of human interleukin 3, macrophage and granulocyte-macrophage colony-stimulating factor on monocyte function following autologous bone marrow transplantation. (1992) (21)
A non-myeloablative conditioning regimen in allogeneic stem cell transplantation from related and unrelated donors in elderly patients. (2006) (21)
Soluble interleukin-6 receptors in hematology patients undergoing bone marrow transplantation. (1996) (20)
Tumor‐cell vaccination induces tumor dormancy in a murine model of B‐cell leukemia/lymphoma (BCL1) (1996) (20)
Adoptive immunotherapy with haploidentical allogeneic peripheral blood lymphocytes following autologous bone marrow transplantation. (2000) (20)
Functional long-term thymidine kinase suicide gene expression in human T cells using a herpesvirus saimiri vector (2000) (20)
Higher than expected transplant-related mortality and relapse following nonmyeloablative stem cell transplantation for lymphoma adversely effects progression free survival. (2000) (20)
Immunotherapy in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma. (1998) (20)
Partial protection of rat parotid glands from irradiation-induced hyposalivation by manganese superoxide dismutase. (2000) (20)
The immunomodulator Linomide: role in treatment and prevention of autoimmune diabetes mellitus. (2001) (20)
Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man (2000) (20)
Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen (2007) (20)
Obstructive jaundice associated with carcinoma of the prostate. (1975) (20)
The role of thiotepa in allogeneic stem cell transplantation in patients with leukemia. (1999) (20)
Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders. (2003) (19)
Second transplantation using allogeneic peripheral blood stem cells in a β‐thalassaemia major patient featuring stable mixed chimaerism (1996) (19)
Treatment of pure red-cell aplasia following major ABO-mismatched T-cell-depleted bone marrow transplantation (1991) (19)
The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases (1999) (19)
Nonmyeloablative stem cell transplantation for the treatment of cancer and life-threatening nonmalignant disorders: past accomplishments and future goals (2001) (19)
Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR. (2012) (19)
Ciprofloxacin enhances hematopoiesis and the peritoneal neutrophil function in lethally irradiated, bone marrow-transplanted mice. (1994) (19)
Split Immunity: Immune Inhibition of Rat Gliomas by Subcutaneous Exposure to Unmodified Live Tumor Cells (2011) (19)
Therapeutic potential of recombinant granulocyte-macrophage colony-stimulating factor and interleukin-3 in murine B-cell leukemia. (1988) (19)
Differential killing of murine B-cell leukemia (BCL1) by photosensitization with merocyanine 540: implications for autologous bone marrow transplantation. (1989) (19)
Detection of minimal residual disease after sex-mismatch bone marrow transplantation in chronic myelogenous leukemia by fluorescence in situ hybridization. (1994) (18)
Hematopoietic stem cell transplantation in multiple sclerosis: experimental evidence to rethink the procedures (2004) (18)
Mixed cryoglobulinemia with a monoclonal IgM component, associated with chronic liver disease. (1972) (18)
Toward amplification of a graft-versus-leukemia effect while minimizing graft-versus-host disease. (2000) (18)
The role of antibodies to IL-2 receptor and Asialo GM1 on graft-versus-leukemia effects induced by bone marrow allografts in murine B cell leukemia. (1995) (18)
Treatment of Leukemia by Alloreactive Lymphocytes and Nonmyeloablative Stem Cell Transplantation (2002) (18)
Interleukin-7-enhanced cytotoxic T lymphocyte activity after viral infection in marrow transplanted mice (1997) (18)
A Randomized Controlled Multicenter Study Comparing Recombinant Interleukin 2 (rIL-2) in Conjunction With Recombinant Interferon Alpha (IFN-α) Versus no Immunotherapy for Patients With Malignant Lymphoma Postautologous Stem Cell Transplantation (2010) (18)
Bone marrow transplantation from a cadaveric donor (1998) (18)
Use of total lymphoid irradiation in tissue transplantation in mice. (1977) (17)
Salivary immunoglobulins in recipients of bone marrow grafts. I. A longitudinal follow-up. (1994) (17)
Mycophenolate mofetil does not suppress the graft-versus-leukemia effect or the activity of lymphokine-activated killer (LAK) cells in a murine model (2005) (17)
Heparanase prevents the development of type 1 diabetes in non‐obese diabetic mice by regulating T‐cell activation and cytokines production (2008) (17)
Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study (2010) (17)
Prevention of autoimmune diabetes by linomide in nonobese diabetic (NOD) mice is associated with up-regulation of the TCR-mediated activation of p21(ras). (1996) (17)
Treatment of chronic myelogenous leukemia with recombinant human interleukin-2 and interferon-alpha 2a. (1994) (17)
Clinical Outcomes of Patients with Desmoplastic Small Round Cell Tumor of the Peritoneum Undergoing Autologous HCT: a CIBMTR Retrospective Analysis (2012) (17)
Ketotifen therapy in chronic graft‐versus‐host disease (cGVHD): effect on mast cells and fibroblasts (1995) (17)
Optimal time interval between myeloablative whole body irradiation and reconstitution with syngeneic bone marrow graft. (1988) (16)
Immunoglobulins A, G, and M to cytomegalovirus during recurrent infection in recipients of allogeneic bone marrow transplantation. (1991) (16)
Potential use of interleukin-6 in bone marrow transplantation: effects of recombinant human interleukin-6 after syngeneic and semiallogeneic bone marrow transplantation in mice. (1994) (16)
Role of interleukin-2 in human hematological malignancies (1995) (16)
Heparanase Promotes Engraftment and Prevents Graft versus Host Disease in Stem Cell Transplantation (2010) (16)
Gammopathy in liver disease. (1972) (16)
RHU GM-CSF shortens aplasia duration after ABMT in non-Hodgkin's lymphoma: a randomized placebo-controlled double-blind study. (1991) (16)
Excellent outcome of non-myeloablative stem cell transplant (NMSCT) for good risk myeloma: The EBMT experience (2000) (16)
Successful treatment of autoimmune manifestations in MRL/l and MRL/n mice using total lymphoid irradiation (TLI). (1983) (16)
Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia (2005) (16)
Kidney allograft survival in dogs treated with total lymphoid irradiation. (1981) (16)
Smarter rather than stronger treatment of haematological malignancies and non-malignant indications for stem-cell transplantation (2004) (16)
Non-myeloablative allogeneic stem cell transplantation focusing on immunotherapy of life-threatening malignant and non-malignant diseases. (2001) (16)
Minimal residual disease in murine B-cell leukemia (BCL1) detected by PCR. (1993) (15)
IL-2-targeted therapy ameliorates the severity of graft-versus-host disease: ex vivo selective depletion of host-reactive T cells and in vivo therapy. (2012) (15)
Telomerase activity and expression in adult human mesenchymal stem cells derived from amyotrophic lateral sclerosis individuals. (2009) (15)
Lectin separation of nonlymphoid suppressor cells induced by total lymphoid irradiation (1985) (15)
Bone marrow transplantation in thalassaemia. (1986) (15)
Human Peripheral Blood Mononuclear Cells Incubated in Vasculogenic Conditioning Medium Dramatically Improve Ischemia/Reperfusion Acute Kidney Injury in Mice (2018) (15)
Bone marrow transplantation with T-cell-depleted grafts. I. Reconstitution of immunohemopoietic functions in lethally irradiated mice transplanted with unseparated or T-cell-depleted syngeneic bone marrow grafts. (1986) (15)
Purging breast cancer cells in preparation for autologous bone marrow transplantation. (1987) (15)
Graft-versus-Host Disease, the Graft-versus-Leukemia Effect, and Mixed Chimerism following Nonmyeloablative Stem Cell Transplantation (2003) (15)
Interstitial pneumonitis in T cell-depleted bone marrow transplantation. (1988) (14)
Superoxide dismutase inhibits radiation-induced lung injury in hamsters (2004) (14)
Low-dose heparin inhibits acute graft versus host disease in mice. (1993) (14)
Successful T cell-depleted allogeneic bone marrow transplantation in a child with recurrent multiple extramedullary plasmacytomas. (1992) (14)
A lupus-like syndrome due to lbuprofen hypersensitivity. (1980) (14)
Immunomodulation of autoimmunity by linomide. (1995) (14)
Herpesvirus saimiri pathogenicity enhanced by thymidine kinase of herpes simplex virus. (2000) (14)
Potential Use of Interleukin-6 in Bone Marrow Transplantation: Effects of Recombinant Human Interleukin-6 After Syngeneic and Semiallogeneic Bone Marrow Transplantation in Mice (1994) (14)
Depletion of donor-reactive cells as a new concept for improvement of mismatched bone marrow engraftment using reduced-intensity conditioning. (2004) (14)
Preliminary characterization of functional residual host-type T lymphocytes following conditioning for allogeneic HLA-matched bone marrow transplantation (BMT). (1988) (14)
Allogeneic Cell-Mediated Immunotherapy at the Stage of Minimal Residual Disease following High-Dose Chemotherapy Supported by Autologous Stem Cell Transplantation (2005) (14)
Allogeneic stem cell transplantation for the treatment of diseases associated with a deficiency in bone marrow products (2004) (13)
New insights into the pathophysiology of gastrointestinal graft-versus-host disease using capsule endoscopy. (2005) (13)
Control of minimal residual cancer by low dose ipilimumab activating autologous anti-tumor immunity. (2014) (13)
Treatment of pure red‐cell aplasia following major ABO‐mismatched T‐cell‐depleted bone marrow transplantation: Two case reports with successful response to plasmapheresis (1991) (13)
Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models. (1999) (13)
Secretion of idiotypic IgM by the mouse B-cell leukaemia (BCL1) occurs spontaneously in vitro and in vivo. (1985) (13)
In vivo T-cell dynamics during immune reconstitution after hematopoietic stem cell gene therapy in adenosine deaminase severe combined immune deficiency. (2011) (13)
Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma. (2009) (13)
Activated long-term peripheral blood cultures as preparation for adoptive alloreactive cell therapy in cancer patients. (1997) (13)
Activated allogeneic cell therapy (allo-ACT) for relapsed chronic myelogenous leukemia (CML) refractory to buffy coat transfusions post-allogeneic bone marrow transplantation. (1996) (13)
Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect. (2004) (13)
Prevention of herpes simplex virus (HSV) infection in recipients of HLA-matched T-lymphocyte-depleted bone marrow allografts. (1988) (13)
The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement? (2008) (13)
Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies. (1996) (13)
Survey on haematopoietic stem cell transplantation for children in Europe (2005) (12)
Allogeneic hematopoietic stem cell transplantation in ovarian cancer—the EBMT experience (2010) (12)
In vivo CAMPATH‐1 monoclonal antibodies: A novel mode of therapy for acute graft‐versus‐host disease (1996) (12)
Immunosuppression and tolerance after total lymphoid irradiation (TLI). (1980) (12)
Removal of breast cancer cells by soybean agglutinin in an experimental model for purging human marrow. (1988) (12)
Elimination of graft versus host disease in matched allogeneic leukemic transplant recipients using CAMPATH-1. (1985) (12)
Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia. (1999) (12)
The use of total lymphoid irradiation (TLI) as immunosuppressive therapy for organ allotransplantation and autoimmune diseases. (1981) (12)
A novel approach for prevention of lethal GVHD by selective elimination of alloreactive donor lymphocytes prior to stem cell transplantation. (2004) (11)
Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation (2001) (11)
Generation of protein-specific and alloantigen-specific suppressor cells following total lymphoid irradiation in mice. (1979) (11)
CD40 ligand-specific antibodies synergize with cyclophosphamide to promote long-term transplantation tolerance across MHC barriers but inhibit graft-vs-leukemia effects of transplanted cells. (2003) (11)
The harvest and use of autologous back-up grafts for graft failure or severe GVHD after allogeneic hematopoietic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (2008) (11)
The use of total lymphoid irradiation for allogeneic bone marrow transplantation in animals and man (1985) (11)
Continuous intravenous administration of rmGM-CSF enhances immune as well as hematopoietic reconstitution following syngeneic bone marrow transplantation in mice. (1993) (11)
Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies (2020) (11)
Murine B-cell leukemia lymphoma (BCL1) cells as a target for NK cell-mediated immunotherapy (2004) (11)
In vitro and in vivo cytokine-induced facilitation of immunohematopoietic reconstitution in mice undergoing bone marrow transplantation. (1988) (11)
Neutropenic enterocolitis and intestinal perforation associated with carboplatin-containing conditioning regimen for autologous bone marrow transplantation. (1992) (11)
Reduced-intensity conditioning or nonmyeloablative stem cell transplantation: introduction, rationale, and historic background. (2004) (11)
The use of total lymphoid irradiation (TLI) for prevention of rejection of T-lymphocyte depleted bone marrow allografts in non-malignant hematological disorders. (1989) (11)
Mesenchymal progenitor cells in red and yellow bone marrow. (2009) (11)
Marrow transplantation in multiple myeloma. (1992) (10)
Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation. (2008) (10)
Improved survival following induction of GVHD following lipopolysaccharide immunization. (2006) (10)
Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Lymphoblastic Leukemia (ALL): A Survey from the European Group for Blood and Marrow Transplantation (EBMT). (2005) (10)
Effect of deoxyspergualin on graft-versus-host disease and graft- versus-leukemia in mice. (1996) (10)
Cytogenetic analysis of the spontaneous murine B-cell leukemia (BCL1). (1980) (10)
Effector cells of graft-versus-host disease, host resistance, and the graft-versus-leukemia effect: summary of a workshop on bone marrow transplantation. (1987) (10)
Induction of graft-versus-leukemia (GVL) effect without graft-versus-host disease (GVHD) by pretransplant donor treatment with immunomodulators. (2009) (10)
Long-term enzyme replacement therapy in beta-glucuronidase--deficient mice by allogeneic bone marrow transplantation. (1982) (10)
The use of recombinant cytokines for enhancing immunohematopoietic reconstitution following bone marrow transplantation. II. The influence of lymphokines on CFU-GM colonies from human untreated, ASTA-Z or Campath-1M treated bone marrow. (1990) (10)
Bone marrow transplantation in beta-thalassemia major. The Israeli experience. (1988) (10)
Completely mismatched allogeneic CD3/CD28 cross-linked Th1 memory cells elicit anti-leukemia effects in unconditioned hosts without GVHD toxicity. (2008) (10)
Interleukin-7 induced facilitation of immunological reconstitution of sublethally irradiated mice following treatment with alloreactive spleen cells in a murine model of B-cell leukemia/lymphoma (BCL1) (2007) (10)
Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease. (2005) (10)
Effect of various cytokine combinations on induction of non-MHC-restricted cytotoxicity. (1993) (10)
Effect of bone marrow T lymphocytes treated with CAMPATH 1G on megakaryocyte colony formation. (1993) (10)
Activation of the recombination activating gene 1 (RAG-1) transcript in bone marrow of senescent C57BL/6 mice by recombinant interleukin-7. (1999) (10)
Successful treatment of diabetes in NOD mice with advanced disease by islet isografts following immunoregulation with Linomide (quinoline-3-carboxamide). (1996) (10)
Non-myeloablative stem cell transplantation for the treatment of cancer and life-threatening non-malignant disorders; past accomplishments and future goals. (2002) (10)
Herbal flavonoids inhibit the development of autoimmune diabetes in NOD mice: proposed mechanisms of action in the example of PADMA 28 (2010) (10)
Future strategies in hematopoietic stem cell transplantation for rheumatoid arthritis. (2001) (10)
Total lymphoid irradiation, anti-lymphocyte globulin and Campath 1-G for immunosuppression prior to bone marrow transplantation for aplastic anemia after repeated graft rejection. (1994) (9)
Prevention and treatment of relapse by bone marrow transplantation. (1993) (9)
Non-myeloablative allogeneic stem cell transplantation for the treatment of patients with chronic myeloid leukemia (2000) (9)
The novel immunomodulator, Linomide, stimulates interleukin-2-induced human natural killer (NK) cell and PHA-stimulated T cell proliferation from normal donors. (1996) (9)
Hemopoietic activity in bone marrow chimeras prepared with total lymphoid irradiation (TLI). (1982) (9)
Immunosuppression and Organ Transplantation Tolerance Using Total Lymphoid Irradiation (1980) (9)
Intrahepatic arterial administration of low-dose methotrexate in patients with severe hepatic graft-versus-host disease: an open-label, uncontrolled trial. (2004) (9)
Long-Term Safety and Efficacy of Gene Therapyfor Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (2009) (9)
Natural cell-mediated cytotoxicity in mice treated with total lymphoid irradiation (TL1). (1982) (9)
Use of total lymphoid irradiation (TLI) in bone marrow and organ transplantation. (1979) (9)
Current problems and future goals in clinical bone marrow transplantation. (1988) (9)
In-vitro T cell mediated function in patients with active rheumatoid arthritis. (1981) (9)
A case of adrenogenital syndrome with aberrant 11beta-hydroxylation. (1977) (9)
Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation? (2006) (8)
Post-hematopoietic stem cell transplantion immune-mediated cytopenias. (2009) (8)
Induction of mixed hematopoietic chimerism and specific transplantation tolerance to allogeneic and xenogeneic grafts by selective elimination of donor-reactive host cells following nonmyeloablative conditioning. (1997) (8)
The effect of in vitro T lymphocyte depletion on generation of IL2-activated cytotoxic cells. (1991) (8)
Cell mediated autoimmune granulocytopenia in a case of Felty's syndrome. (1980) (8)
Non-myeloablative stem cell transplantation for induction of host-versus-graft tolerance for adoptive immunotherapy of malignant and nonmalignant diseases and towards transplantation of organ allografts. (2002) (8)
Pretransplant treatment of donors with immunomodulators to control graft-versus-host disease (GVHD) in transplant recipients. (2007) (8)
Monoclonal rat anti-human lymphocyte antibody Campath-1 binds to T and B lymphocytes but effectively lyses only T cells. (1987) (8)
Immunohematopoietic reconstitution by allogeneic and autologous bone marrow grafts as a means for induction of specific unresponsiveness to donor-specific allografts and modified self in autoimmune disorders. (1993) (8)
Induction of graft versus leukemia effects by cell-mediated lymphokine-activated immunotherapy after syngeneic bone marrow transplantation in murine B cell leukemia (1996) (8)
Salivary immunoglobulins in recipients of bone marrow grafts. II. Transient secretion of donor-derived salivary IgA following transplantation of T cell-depleted bone marrow. (1994) (8)
Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-α2a and interleukin-2 (1992) (8)
Reduced intensity versus truly nonmyeloablative conditioning for stem-cell transplant recipients. (2004) (8)
Synthetic, Non-Natural Analogs of Ceramide Elevate Cellular Ceramide, Inducing Apoptotic Death to Prostate Cancer Cells and Eradicating Tumors in Mice (2010) (8)
Bone marrow transplantation with T-cell-depleted grafts. II. Reconstitution of immunohemopoietic functions in lethally irradiated mice transplanted with unseparated or T-cell-depleted bone marrow grafts disparate at minor histocompatibility antigens. (1987) (8)
Control of relapse due to minimal residual disease (MRD) by cell-mediated cytokine-activated immunotherapy in conjunction with bone marrow transplantation. (1991) (8)
Spontaneous murine b cell leukemia (mbl1). An animal model for human chronic lymphocytic leukemia. Abstr. (1978) (8)
Immune modulation by ionized irradiation. (1988) (8)
Membrane Type 1-Matrix Metalloproteinase Is Directly Involved in G-CSF Induced Human Hematopoietic Stem and Progenitor Cell Mobilization. (2004) (8)
P-261 Ovarian failure post-chemotherapy in young cancer patients-risk assessment indicate the need for intervention (1997) (7)
Human T cells recovered from human/Balb radiation chimeras are hypersensitive to human immunodeficiency virus type 1 infection (1997) (7)
Treatment of Resistant Leukemia by rIL-2 Activated NK Cells in Recipients of HLA Matched and Haploidentically Mismatched Stem Cell Allografts while Avoiding GVHD. (2004) (7)
Use of matched or mismatched rIL-2 activated donor lymphocytes positively selected for CD56+ for immunotherapy of resistant leukemia after allogeneic stem cell transplantation (2004) (7)
Irradiated mononuclear cells express significant in vitro cytotoxic activity: promise for in vivo clinical efficacy of irradiated mismatched donor lymphocytes infusion. (2014) (7)
Mechanisms of transplantation tolerance to allogeneic bone marrow cells following total lymphoid irradiation (TLI). (1980) (7)
Human mesenchymal stromal cells ameliorate complement induced inflammatory cascade and improve renal functions in a rat model of ischemia-reperfusion induced acute kidney injury (2019) (7)
Correlation between enhancement of graft-versus-leukemia effects following allogeneic bone marrow transplantation by rIL-2 and increased frequency of cytotoxic T-lymphocyte precursors in murine myeloid leukemia. (2000) (7)
Transient elevation of serum lactic dehydrogenase following autologous bone marrow transplantation. (1991) (7)
Eosinophils activation in post-autologous bone marrow transplanted patients treated with subcutaneous interleukin-2 and interferon-alpha 2A immunotherapy. (1994) (7)
Cytokine-mediated immunotherapy following autologous bone marrow transplantation in lymphoma and evidence of interleukin-2-induced immunomodulation in allogeneic transplants. (1997) (7)
Spinal epidural lipomatosis following haploidentical allogeneic bone marrow transplantation for non‐Hodgkin lymphoma (2004) (7)
Allogeneic bone marrow transplantation without graft-v-host disease: true tolerance of graft against the host through depletion of donor T lymphocytes pregrafting in malignant and nonmalignant disorders. (1987) (7)
Interleukin-3 in combination with granulocyte-macrophage-colony-stimulating factor following bone marrow transplantation in a radiation accident victim (1994) (7)
Lectin-binding properties of Burkitt's lymphoma cell lines: application to bone marrow purging. (1990) (7)
Total lymphoid irradiation (TLI) and allogeneic marrow transplantation for enzyme replacement therapy and immunotherapy of leukemia in mice. (1981) (7)
CD44 gene vaccination for insulin-dependent diabetes mellitus in non-obese diabetic mice. (2008) (7)
Minitransplants and cell-based therapies for malignant and nonmalignant disorders (1999) (7)
Rapid and Wide Immunereconstitution Obtained with HSV-TK Engineered Donor Lymphocyte Add-Backs Permits Long-Term Survival after haplo-HSCT. (2006) (7)
Long-term effects of splenectomy on immunocompetent cells of adult mice. (1980) (7)
Recombinant Human Interleukin-6 Accelerates In-Virto Megakaryocytopoiesis and Platelet Recovery Post Autologous Peripheral Blood Stem Cell Transplantion (1995) (7)
Immunotherapy in conjunction with autologous bone marrow transplantation. (1990) (7)
A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation (2003) (6)
Soluble IL-6 receptors (sIL-6R) in hematological patients receiving immunotherapy with IL-2/IFN-alpha or donor lymphocytes following bone marrow transplantation. (1996) (6)
The importance of patient selection in nonmyeloablative stem cell transplant (NMSCT) for acute and chronic leukaemia, myelodysplastic syndrome, and myeloma (2000) (6)
Maternal-fetal relationship, natural chimerism and bilateral transplantation tolerance as the basis for non-myeloablative stem cell transplantation (2002) (6)
Enrichment for GM-CFU from human bone marrow using Sambucus nigra agglutinin: potential application to bone marrow transplantation. (1986) (6)
The CRST syndrome. (1971) (6)
Immunomodulatory effects of linomide in animals immunized with immunopathogenic retinal antigens: dissociation between different immune functions (1997) (6)
Hematopoietic stem cell therapy for malignant diseases (2007) (6)
Involvement of interleukin-2 in immunologic reconstitution following bone marrow transplantation in mice. (1995) (6)
Normal hematopoietic reconstitution following ASTA-Z 7557-purged grafts in the absence of in vitro CFU-GM colony growth. (1993) (6)
N-acetylcysteine mildly inhibits the graft-vs.-leukemia effect but not the lymphokine activated cells (LAK) activity. (2007) (6)
Differential effects of CD4+ and CD8+ cells on lymphocyte development from human cord blood cells in murine fetal thymus explants. (1999) (6)
Nonmyeloablative bone marrow transplantation based on deletion of host-anti-donor alloreactive cells prevents autoimmune insulitis and diabetes in nonobese diabetic mice. (2002) (5)
Immunoregulation of GVHD by triggering the innate immune system with CpG (2009) (5)
Induction of Bilateral Transplantation Tolerance to Cellular and Perfused Allografts and Xenografts with Donor Hematopoietic Cells a (1998) (5)
Inhibition of leukemic cell proliferation by one or more factors released from splenic BCL1 cells. (1995) (5)
The Use of Soybean Agglutinin (SBA) for Bone Marrow (BM) Purging and Hematopoietic Progenitor Cell Enrichment in Clinical Bone Marrow Transplantation. (1999) (5)
Combination of magnetic and chemocytotoxic cancer cell depletion for autologous bone marrow transplantation. (1988) (5)
Transplantation of hematopoietic stem cells for induction of unresponsiveness to organ allografts (2004) (5)
The effect of T lymphocyte depletion on susceptibility to influenza virus infection and development of anti-viral immunity in lethally irradiated mice reconstituted with syngeneic bone marrow grafts. (1987) (5)
Intraportal and systemic allogeneic cell therapy in a murine model of hepatic metastatic breast cancer. (2002) (5)
Lessons from bone marrow transplantation for a victim of a radiological accident with acute radiation syndrome (2005) (5)
The effect of high-dose thiotepa, alone or in combination with other chemotherapeutic agents, on a murine B-cell leukemia model simulating autologous stem cell transplantation (2007) (5)
Deletion of donor-reactive cells as a new conditioning regimen for allogeneic bone marrow transplantation. (2007) (5)
The effect of pegylated antisense acetylcholinesterase on hematopoiesis. (2003) (5)
Time to engraftment following allogeneic stem cell transplantation is significantly longer in patients with myelodysplastic syndrome than with acute myeloid leukemia (2008) (5)
Failure of cyclosporine to induce graft-vs-host disease or graft-vs-leukemia after syngeneic bone marrow transplantation in mice. (1996) (4)
Donor lymphocyte infusions for hematopoietic malignancy. (2002) (4)
Should soybean agglutinin purging be performed in breast cancer patients undergoing autologous stem cell transplantation? A retrospective analysis of 48 patients. (1997) (4)
Cytokine gene transduction into non-immunogeneic murine tumor cells. (1998) (4)
Intra-Arterial Catheter Directed Immunosuppressive Therapy for Steroid Resistant or Dependent Graft vs. Host Disease (GVHD). (2007) (4)
The role of thiotepa in autologous bone marrow transplantation for acute leukemia. (1998) (4)
Effect of Linomide on adhesion molecules, TNF-α, nitrogen oxide, and cell adhesion (2005) (4)
Autologous and Allogenic Stem Cell Transplantation for the Treatment of Autoimmune Diseases as a Potential New Approach (1999) (4)
Multiformic modulation of endotoxin effects by linomide. (1999) (4)
Clinical implications of monoclonal gammopathy in chronic liver disease (1974) (4)
Immunotherapy of murine leukemia following non-myeloablative conditioning with naïve or G-CSF mobilized blood or bone marrow stem cells (2004) (4)
A method for isolating pluripotent/multipotent stem cells from blood by using the pluripotent and germ-line DAZL gene as a marker. (2009) (4)
Development of Secondary Anaplastic Oligoastrocytoma after Matched Unrelated Bone Marrow Transplantation in a Child with Acute Myeloid Leukemia (2003) (4)
Induction of tumor immunity by intact irradiated leukemic B cells (BCL1) bearing a tumor-associated cell-surface idiotype and the costimulatory B7 molecule (1995) (4)
Autologous bone marrow transplantation for stage IV neuroblastoma: the role of soybean agglutinin purging. (1993) (4)
The effect of total or partial T lymphocyte depletion on susceptibility to influenza virus infection and development of antiviral immunity in lethally irradiated mice reconstituted with immune syngeneic bone marrow grafts. (1991) (4)
The effect of linomide, an immunoregulator in experimental autoimmune diseases, on humoral antibody responses in mice. (1997) (4)
Induction of cell-mediated IL-2-activated antitumor responses in conjunction with autologous and allogeneic bone marrow transplantation. (1991) (4)
Toward improvement of therapeutic strategies in leukemia by amplification of the immune responses against leukemia. (1990) (3)
Regulation of the immune response in experimental models of autoimmune disorders: resistance of (NZB X NZW)F1 mice to tolerance induction in vivo. (1983) (3)
379: Intra-arterial Catheter Directed Immunosuppressive Therapy for Steroid Resistant or Dependent Graft vs. Host Disease (GVHD) (2008) (3)
Interleukin 2 regulation following semi-allogeneic bone marrow transplantation in mice (2006) (3)
Trisenox (Arsenic Trioxide) in the Treatment for Multiple Myeloma after Bone Marrow Transplantation. (2005) (3)
Continuous Interleukin-2 Infusion Combined with Cyclophosphamide- Based Combination Chemotherapy in the Treatment of Hemato-Oncological Malignancies (1998) (3)
Review : Modulation of experimental systemic lupus erythematosus with linomide (1996) (3)
Selective elimination of alloreactivity in vitro and in vivo while sparing other T-cell-mediated immune responses (2012) (3)
Salivary immunoglobulins in recipients of bone marrow grafts. III. A longitudinal follow-up of CMV specific antibodies. (1996) (3)
New approaches for control of anti-self-reactivity in type 1 diabetes and transplantation of pancreatic islets. (1997) (3)
A Phase II Multicenter Trial of HSV-TK Engineered Donor Lymphocytes after Haplo-Identical HSCT: Early Immune Reconstitution and Abrogation of Gvhd. (2004) (3)
Inhibition of Tumors in Mice Models by a Synthetic Ceramide-analog AD2725 (2016) (3)
Bone Marrow Transplantation for Cancer and Autoimmunity (2000) (3)
Depletion of alloantigen-primed lymphocytes overcomes resistance to allogeneic bone marrow in mildly conditioned recipients. (2004) (3)
The Impact of Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents with Recurring Hodgkin’s Lymphoma: An EBMT Study on 151 Patients. (2007) (3)
Induction of transplantation tolerance by intraportal injection of allogeneic bone marrow cells: Possible implications for intrauterine bone marrow transplantation across major histocompatibility barriers (1988) (3)
Protooncogenes and autoimmunity. (1997) (3)
ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA USING CAMPATH-1 MONOCLONAL-ANTIBODIES AND POSTTRANSPLANT ALLOIMMUNIZATION WITH DONOR LYMPHOCYTES (1993) (3)
Selective abrogation of alloreactivity via priming in the presence of aphidicolin, a specific inhibitor of DNA polymerase. (1989) (3)
Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia. (2006) (3)
RESISTANCE OF T SUPPRESSOR CELLS TO CYCLOPHOSPHAMIDE ADMINISTRATION IN TOTAL‐LYMPHOID-IRRADIATED MICE (1983) (3)
Induction of transplantation tolerance by intraportal injection of allogeneic bone marrow cells (1988) (3)
Successful Treatment of Diabetes in Nod Mice with Advanced Disease by Islet Isografts following Immunoregulation with Linomide (Quinoline-3-Carboxamide) (1996) (3)
Single and double stranded DNA binding lymphocytes in the peripheral blood of patients with systemic lupus erythematosus and normal controls. (1979) (3)
Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments. (1999) (3)
Regulation of the immune response in experimental models of autoimmune disorders: I. Immunocompetence and transplantation tolerance in female (NZB X NZW)F1 hybrid mice immunosuppressed with total lymphoid irradiation and in reconstituted bone marrow chimeras. (1983) (3)
The role of recombinant cytokines and other immunomodulators on engraftment following allogeneic bone marrow transplantation in mice. (1992) (3)
Ganciclovir for the treatment of disseminated CMV disease without pneumonia in allogeneic T-lymphocyte depleted bone marrow transplantation. (1993) (3)
New approaches for control of anti-self reactivity in type 1 diabetes mellitus and transplantation of pancreatic islets (1999) (3)
Successful matched unrelated transplantation from a donor with idiopathic thrombocytopenic purpura (ITP) (1995) (3)
Effects of interleukin 2 on engraftment following autologous bone marrow transplantation (ABMT) in dogs. (1992) (3)
Reactivity of Human Monoclonal Antibody Campath-1 with Human Leukemia Lymphoma Cell Lines of Varying Maturation. (1990) (3)
Investigations on the role of inflammatory and anti-inflammatory agents on the treatment of murine B cell leukemia by recombinant human interleukin-2. (1993) (2)
Donor activating KIR influence outcome post unrelated stem cell transplantation (2004) (2)
A 2‐DAY MLR PROCEDURE FOR MARROW DONOR SELECTION FOR ALLOGENEIC BONE MARROW TRANSPLANTATION (1993) (2)
Severe migratory polyarthritis following in vivo CAMPATH-1G. (1995) (2)
Is There a Role for ASCT in Patients with Desmoplastic Small Round Cell Tumor of the Peritoneum (2011) (2)
The clinically validated viral superinfection therapy (SIT) platform technology could cure early cases of COVID-19 disease (2021) (2)
INTERLEUKIN-18 (IL-18) And IL-18 binding protein (IL-18bp) And acute graft versus host disease (Gvhd) (2000) (2)
HSV-TK Engineered Donor Lymphocytes Add-Backs Reduce Late Mortality and Improve Survival of High Risk Acute Leukemia after Haplo-HSCT: Results of a Phase II Multicenter Trial. (2005) (2)
Suppressor T cells in allogeneic bone marrow chimeras. (1987) (2)
Anti-rIL-2 receptor antibodies and marrow aplasia (2003) (2)
ANTILEUKEMIC EFFECTS OF ALLOGENEIC BONE MARROW ALLOGRAFTS IN MICE (1982) (2)
Rhinolalia as a presenting sign of pneumomediastinum complicating post peripheral blood stem cell transplantation bronchiolitis obliterans (2003) (2)
Linomide administration following bone marrow transplantation in mice (2002) (2)
Chronic liver disease associated with mixed cryoglobulinemia. Review of the literature and presentation of two cases. (1972) (2)
[Bone marrow transplantation]. (1995) (2)
Serum transcobalamin levels as an early indicator of bone marrow engraftment following transplantation (1983) (2)
Infusions of HSV-TK Engineered Donor Lymphocytes Effectively Protect Patients Undergoing Haploidentical Stem Cells Trasplantation (HSCT) from Infectious Mortality. (2007) (2)
Nonmyeloablative stem cell transplantation using lymphoablative rather than myeloablative conditioning in the prefludarabine era by ATG and limiting doses of cyclophosphamide (2005) (2)
Effect of total lymphoid irradiation on natural killer cells and cytotoxic and primed T lymphocytes. (1994) (2)
Enhancement of hematopoietic reconstitution with recombinant cytokines: effect of rhIL-6 in combination with rhGM-CSF and rhIL-3 on unmodified or T cell-depleted bone marrow. (1999) (2)
380: Alefacept Treatment for Chronic Extensive Graft Versus Host Disease (2008) (2)
Immunoregulation rather than immunosuppression for prevention and treatment of autoimmune disorders. (1996) (2)
Effect of recombinant human manganese superoxide dismutase on radiosensitivity of murine B cell leukemia (BCL1) cells. (1993) (2)
Cell-mediated immunity in idiopathic autoimmune haemolytic disease. (1975) (2)
Prevention of allograft rejection by induction of specific transplantation tolerance with immunomanipulation using total lymphoid irradiation. (1980) (2)
Bone marrow transplantation in beta-thalassemia major with prevention of graft-vs-host disease. (1988) (2)
The role of activated T lymphocytes in megakaryocytopoiesis (1992) (2)
Normalization of serum lactic dehydrogenase in β‐thalassemia patients following bone marrow transplantation (1996) (2)
The role of suppressor T lymphocytes in the maintenance of tolerance to alloantigens in bone marrow chimeras prepared with total lymphoid irradiation (TLI). (1985) (2)
Recombinant human interleukin-6 accelerates in-vitro megakaryocytopoiesis and platelet recovery post autologous peripheral blood stem cell transplantation. (1995) (2)
The Use of Bone Marrow Derived Mesenchymal Stromal Cells for Treatment of Patients with Multiple Sclerosis and Neurodegenerative Disorders – Achievements and Future Goals (2012) (1)
Towards Possible Cure of Cancer by Immunotherapy of Minimal Residual (2015) (1)
Use of total lymphoid irradiation (TLI) for the treatment of autoimmune disorders. (1988) (1)
[Aplastic anemia following acute viral hepatitis associated with hypogammaglobulinemia--attempted treatment by bone marrow transplantation]. (1975) (1)
Transfer of B memory cells to a T-dependent antigen in murine bone marrow transplantation. (1987) (1)
BONE MARROW TRANSPLANTATION WITH T‐CELL-DEPLETED GRAFTS (1986) (1)
Non-myeloblative stem-cell transplantation for immunotherapy of cancer and non-malignant diseases with allogeneic lymphocytes. (2002) (1)
MIXED CHIMERISM FOLLOWING NON- MYELOABLATIVE STEM CELL TRANSPLANTATION (NST) TO INDUCE TRANSPLANTATION TOLERANCE TO BONE MARROW AND ORGAN ALLOGRAFTS (2000) (1)
The use of parabiosis for investigating the mechanism of transplantation tolerance in bone marrow chimeras induced by total lymphoid irradiation (1990) (1)
Total lymphoid irradiation used as an experimental method of immunosuppression therapy in bone marrow and whole organ allotransplantation (1978) (1)
305: Thymoglobulin® Rabbit Anti-thymocyte Globulins (r-ATG) Induces Faster Platelet Recovery and does not Suppress Granulocyte Engraftment in a Non-myeloablative Stem Cell Transplantation Setting (2008) (1)
Shifting Towards Better Immunotherapy Rather Than More Intensive Chemoradiotherapy Using a Non-Myeloablative Approach in Patients with Leukemia (2001) (1)
Excretion of liver antigens in the urine of patients with hepatic diseases (1976) (1)
A clinically validated, broadly active, oral viral superinfection therapy could mitigate symptoms in early-stage COVID-19 patients. (2022) (1)
Allogeneic stem cell transplantation (SCT) from hla matched family donors other than siblings (2000) (1)
Deletion of donor-reactive cells followed by stem cell transplantation in recipients treated with total lymphoid-irradiation as a means for induction of transplantation tolerance to organ allografts and xenografts. (1998) (1)
Targeting non-engrafting IL-2 activated intentionally mismatched donor lymphocytes with monoclonal or bispecific antibodies for treatment of otherwise incurable cancer. (2020) (1)
Depletion of human lymphocytes from peripheral blood and bone marrow by affinity ligands conjugated to agarose—polyacrolein microsphere beads (1986) (1)
Depletion of alloreactive T cells for tolerance induction in a recipient of kidney and hematopoietic stem cell transplantations (2012) (1)
HLA and acute graft vs host disease (GVHD) following allogeneic bone marrow transplantation (BMT) (1994) (1)
Non-myeloablative stem cell transplantation (Nst) For the treatment of malignant and non-malignant diseases (2000) (1)
lymphoma: myeloablative or reduced intensity? Conditioning regimens for allotransplants for diffuse large B-cell (2012) (1)
Optimization of conditioning therapy for leukemia prior to BMT. I. Optimal synergism between cyclophosphamide and total body irradiation for eradication of murine B cell leukemia (BCL1). (1993) (1)
Fludarabine based low intensity conditioning protocol for unrelated matched stem cell transplantation (NST/MUD) in chronic myelogenous leukemia(CML) (2000) (1)
Prevention and treatment of type I diabetes in NOD mice by linomide. (1995) (1)
Adoptive transfer of resistance to Pseudomonas aeruginosa infection by splenocytes and bone marrow cells from BALB/c mice immunized by pseudomonas aeruginosa lectin preparations (1989) (1)
Successful engraftment following allogeneic stem cell transplantation in very high-risk patients with busulfan as a single agent. (2005) (1)
Erratum to: Preimplantation factor (PIF) analog prevents type I diabetes mellitus (TIDM) development by preserving pancreatic function in NOD mice (2011) (1)
Use of matched or mismatched rIL-2 activated donor lymphocytes positively selected for CD56+ for immunotherapy of resistant leukemia after allogeneic stem cell transplantation. (2004) (1)
Total Lymphoid Irradiation for Immunosuppression (1985) (1)
SUPPRESSOR MECHANISMS IN TISSUE TRANSPLANTATION TOLERANCE FOLLOWING TOTAL LYMPHOID IRRADIATION (TLI) (1979) (1)
Induction of tolerance to self antigens through bone marrow transplantation (BMT) as a therapeutic approach in acute and chronic relapsing (CR-EAE) experimental autoimmune encephalomyelitis (1991) (1)
[Human umbilical cord blood as a source of hematopoietic progenitor cells for transplantations]. (1995) (1)
A CASE OF ADRENOGENITAL SYNDROME WITH ABERRANT (2008) (0)
Modulation of immunoreactivity towards transplantation tolerance across mhc using total lymphoid irradiation. Abstr. (1981) (0)
Reactivity in a modified MLR test correlates with bone marrow transplantation outcome in patients (1992) (0)
Tolerance in bone marrow & organ transplantation : achievements & goals (1984) (0)
BONE MARROW TRANSPLANTATION: EXPERIMENTAL AND CLINICAL ASPECTS (1982) (0)
Chemotherapy Foundation: Innovative Cancer Therapy for Tomorrow--XVII Symposium. 3-6 November 1999, Mount Sinai School of Medicine, New York, NY, USA. (2000) (0)
Duration to Engraftment Requires Significantly Much More Time in Myelodysplastic Syndrome (MDS) Patients as Compared to Acute Myeloid Leukemia (AML) Patients Following Allogeneic Stem Cell Transplantation. (2005) (0)
Allogeneic Hematopoietic Stem Cell Transplantation for Autoimmune Diseases (2019) (0)
Protective role of bone marrow cells in controlling alloreactivity. (2003) (0)
[Hematopoietic growth factor (GM-CSF) after autologous bone marrow transplantation. A randomized, double-blind, multicenter study in 91 cases of non-Hodgkin's malignant lymphomas]. (1993) (0)
CD 44 Gene Vaccination for Insulin-Dependent Diabetes Mellitus in Non-Obese Diabetic Mice (0)
Immunologic approaches for breast cancer patients in the setting of stem cell transplantation (1999) (0)
Transplantation from Related and Unrelated Donors in Elderly Patients - Equal Toxicity and Survival. (2006) (0)
Simultaneous Haploidentically Mismatched Stem Cell Transplantation from Multi-Donors (MDT) in Humans Offers Better Engraftment as Compared to Single Haploidentical Donor. (2007) (0)
Towards Possible Cure of Cancer by Immunotherapy of Minimal Residual Disease Using Intentionally Mismatched Donor Lymphocytes (2020) (0)
400 Four-month outcome and safety of intracoronary autologous bone marrow infusion for the treatment of sever ischemic cardiomyopathy with evidence of hibernating myocardium (2004) (0)
The use of fludarabine based reduced intensity conditioning for the treatment of patients with Fanconi’s anemia (2004) (0)
Treatment of advanced disease in NOD mice by immunomodulation and expansion of B-cell mass: a combined approach (2009) (0)
Diagnostic, prevention et traitement du diabete (1998) (0)
is significantly longer in patients with myelodysplastic syndrome than with acute myeloid leukemia (2008) (0)
Long-term clinical studies of high-risk renal retransplant recipients given total lymphoid irradiation. (1989) (0)
Long-Term Outcome of Nonmyeloablative Allogeneic Stem Cell Transplantation in First Chronic Phase of Chronic Myeloid Leukemia (2006) (0)
of minimal residual disease in malignant hematologic disorders control syngeneic bone marrow transplantation in mice as a model for Use of recombinant human interleukin-2 in conjunction with (2011) (0)
Post-irradiated canine serum (PICS-J) stimulates megakaryocyte (MK) progenitors and thrombopoiesis in-vitro (1996) (0)
Innovative immunotherapy for prevention and treatment of relapse following conventional chemotherapy or stem cell transplantation (2016) (0)
Abstract session I–Transplantation (2004) (0)
1004. Integration Analyses in ADA-Deficient SCID Patients Successfully Treated with Stem Cell Gene Therapy (2004) (0)
296: Simultaneous Haploidentically Mismatched Stem Cell Transplantation from Multi-donors (MDT) in Humans Offers better Engraftment as Compared to Single Haploidentical Donor (2008) (0)
Feasibility and toxicity of high-dose chemotherapy with/without BCNU for autologous bone marrow transplantation (ABMT) in breast carcinoma (1993) (0)
P085 Treatment of steroid refractory graft vs. host disease by intra-arterial infusion (2007) (0)
20 Years of Experience with Hematopoietic Stem Cell Transplantation for β-Thalassemia Major. (2005) (0)
P083 Simultaneous haploidentically mismatched stem cell transplantation from multi-donors (MDT) in humans offers better engraftment as compared to single donor (2007) (0)
Autologous bone marrow transplantation (ABMT) for non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD): The role of immunotherapy (1993) (0)
Inhibition of Mutant FLT3 Activation by the Novel Tyrphostin, AGS324. (2005) (0)
Is locus C matching important in bone marrow transplantation (1994) (0)
Successful purging of murine plasmacytoma by mafosfamide (ASTA-Z). (1994) (0)
Effect of RTVP-1 on the mesenchymal transformation of glioma stem cells (GSCs) and their self-renewal and migration. (2013) (0)
lymphoma: a double- blind placebo-controlled trial transplantation with unpurged and purged marrow in non-Hodgkin's factor after high-dose chemotherapy and autologous bone marrow Recombinant human granulocyte-macrophage colony-stimulating (2013) (0)
Effect of Linomide on adhesion molecules, TNF-alpha, nitrogen oxide, and cell adhesion. (2005) (0)
Successful treatment of chronic-relapsing experimental autoimmune encephalomyelitis with linomide (LS-2616) (1991) (0)
Leukemia 2000: towards the cure. 7-9 September 2000, Houston, TX, USA. (2000) (0)
Felty ' s syndrome . granulocytopenia in a case of Cell mediated autoimmune (0)
Matching for HLA NK epitopes reduces AGVHD and improves survival in one haplotype matched bone marrow transplants (2003) (0)
BONE MRROY TRANSPLANTATION IN B-TWIASSEUIA UAJOR (1988) (0)
Tumorigenicity and immunogenicity in a murine model of B-cell leukemia/lymphoma (BCL1). (1998) (0)
Allogeneic bone marrow transplatation for correction of enzyme deficiency in mice using total lymphoid irradiation. Abstr. (1980) (0)
Infusion of suicide gene-modified donor T cells promotes a rapid and effective immune reconstitution and provides long-term survival after haploidentical hemaopoietic cell transplantation for the cure of patients with high-risk leukemia (2008) (0)
Cellular Therapy by Non-Myeloablative Stem Cell Transplantation and Immunotherapy of Minimal Residual Disease (1999) (0)
malignancies relapsing post BMT (letter; comment) Allogeneic cell therapy: the treatment of choice for all hematologic (2011) (0)
Quinazolinone-containing drug and methods for their use (1995) (0)
Regulation of the immune response in experimental models of autoimmune disorders. II. Induction of suppressor cells of the mixed lymphocyte culture in adult (NZB x NZW)F1 mice using total lymphoid irradiation. (1983) (0)
Immunotherapy by Allogeneic Lymphocytes and Cytokines Following Autologous and Allogeneic Bone Marrow Stem Cell Transplantation (2020) (0)
5th International Conference on Clinical Hematology and Transfusion Medicine (2020) (0)
Serum cytokines in patients with chronic myelogenous leukemia treated with IL-2 and aIFN (1991) (0)
Triaryl compounds and compositions comprising the same (2008) (0)
Successful engraftment following allogeneic stem cell transplantation with busulfan as a (2005) (0)
allogeneic bone marrow transplantation recombinant human interleukin-2 to treat leukemia relapse after Allogeneic cell therapy with donor peripheral blood cells and (2011) (0)
Adoptive Transfer of Immunity to Hepatitis B Through Bone Marrow Transplantation from Immunized Donors (1994) (0)
State-of-the-Art Review Donor Lymphocyte Infusion: The Use of Alloreactive and Tumor-Reactive Lymphocytes for Immunotherapy of Malignant and Nonmalignant Diseases in Conjunction with Allogeneic Stem Cell Transplantation (2002) (0)
T-cell depleted bone marrow transplantation for plasma cell myeloma (1988) (0)
Donor Immunization Vaccination and Transfer of Donor Immunity to Bone Marrow Transplant Recipients in the Course of Allogeneic Cell Therapy for Prevention and Treatment of Relapse (1998) (0)
Graft-versus-leukemia : experimental results (1993) (0)
[Autologous stem cell transplantation breast cancer with distant metastases]. (1998) (0)
Immunotherapy in high-risk, chemotherapy-resistant patients with metastatic solid tumors and hematologic malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: A phase II study. (2010) (0)
Radiosensitivity and responsiveness to recombinant interleukin-2 of effector cells of graft vs. host disease and mixed lymphocyte reaction in mice. (1992) (0)
Reduced-intensity allografting as first transplantation approach in relapsed/refractory grade 1-2 follicular lymphoma provides improved outcomes in long-term survivors Biol Blood Marrow Transplant (2015) (0)
The Role of Proto-Oncogenes in Autoimmunity (1999) (0)
Fatal acute cardiomyopathy associated with “non‐cardiotoxic” chemotherapy for autologous bone marrow transplantation (1992) (0)
Infusions of HSV-TK genetically modified donor lymphocytes enable a wider use of partially mismatched allogeneic transplantation by reducing infection related mortality and improving survival in high risk acute leukemia. (2006) (0)
88. Antitumor effects of human IL-6 in murine leukemia and solid tumor models (1992) (0)
Bone marrow & organ transplantation : achievements & goals (1984) (0)
Vivo in Inhibition of a von Hippel-Lindau Pheochromocytoma Treatment with Halofuginone Results in Marked Growth (2003) (0)
Unmodified Live Tumor Cells Gliomas by Subcutaneous Exposure to Split Immunity : Immune Inhibition of Rat (2011) (0)
Amplification of Graft vs Malignancy (GVM) Effects by Using Intentionally Mismatched Donor Lymphocytes While Avoiding Graft-vs-Host Disease in Conjunction with Haploidentically Mismatched Stem Cell Allografts in Patients with Hematological Malignances. (2006) (0)
Chapter-08 The Use of Non-myeloablative Stem Cell Transplantation (NST) for the Treatment of Malignant and Non-malignant Diseases (2006) (0)
Bone marrow transplantation across major histocompatibility barriers in mice treated with fractionated total lymphoid irradiation. Abstr. (1977) (0)
Resistance to mycobacteria in mice treated with fractionated total lymphoid irradiation (TLI) and in mice reconstituted with allogenic bone marrow cells following radiotherapy. (1985) (0)
Non-myeloablative stem cell transplantation in newly established donor stromal microenvironment for facilitation of hematopoietic reconstitution (2004) (0)
Effective Treatment of Resistant Hematological Malignancies by IL-2 Activated NK Cells Using Haploidentically Mismatched Donors by Induction of Graft-Versus-Tumor (GVT) Effect While Avoiding GVHD. (2005) (0)
Commentary (Slavin): Nonmyeloablative Preparative Regimens for Allogeneic Hematopoietic Transplantation (2003) (0)
O-148 Prevention of vaginal hemorrhage in thrombocytopenic cancer patients during chemotherapy treatments (1997) (0)
Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma. (2001) (0)
Proceedings of the 2nd Meeting of the Asian Cellular Therapy Organization (2011) (0)
Visualization of immune response kinetics in full allogeneic chimeras. (2011) (0)
Nonmyeloablative Allogeneic Stem Cell Transplantation: Towards Improving Efficacy of Immunotherapy Instead of Myeloablative Chemoradiotherapy (2000) (0)
Allogeneic cell therapy as potential cure of hematologic malignancies (2020) (0)
Breakthrough notions in Hematology and Transfusion Medicine: Market Scrutiny (2020) (0)
[The role of interleukin-2--based immunotherapy in hematological malignancies]. (1996) (0)
Cell therapy of cancer with alloreactive intentionally mismatched IL-2 activated donor lymphocytes targeting anti-cancer killer NK & T cells using monoclonal and bispecific antibodies (2015) (0)
Early and Effective Immune-Recovery by Gene-Engineered Lymphocytes after Haploidentical Transplantation for Leukemia Abate Late Transplant Mortality (2008) (0)
Induction of tumor dormancy in BALB/C mice against nonimmunogenic b cell leukemia (2017) (0)
Stem Cells as Targets for Gene and Cell Therapy (2005) (0)
Efficacy of high dose chemotherapy with/without BCNU for autologous bone marrow transplantation (ABMT) in breast cancer (1993) (0)
Assessment of the Immune Reconstitution by Cylex Immuknow™ Assay in Patients after Allogeneic Stem Cell Transplantation. (2006) (0)
Transient recovery of endogenous immune function following haploidentical peripheral stem cell transplantation in a patient with severe combined immunodeficiency without evidence of engraftment (2000) (0)
The use of melatonin and co-treatment with autologous or allogeneic cells as a model for control of malignant beta-cell leukemia. (1999) (0)
Lymphokine mediated immuno-therapy (1995) (0)
Enhancement of Hematopoietic Stem Cell Engraftment and Graft vs. Leukemia Effect Induced by Matched and Haploidentically Mismatched Allograft Using Multi-Donor Stem Cell Transplantation (MDT). (2006) (0)
LAB-STEM CELLS (2012) (0)
Enhancement of primary and secondary responses to sheep red blood cells and influenza virus in BALB/c mice by recombinant human interleukin-2. (1996) (0)
N-Acetylcysteine Mildly Inhibits the Graft vs Leukemia Effect but Not the Lymphokine Activated Cells (LAK) Activity. (2006) (0)
Megakaryocyie growth factors in sera of throbocytopenic patients undergoing chemotherapy, radiotherapy or allogeneic bone marrow transplantation (1993) (0)
Engraftment following low dose total body irradiation (Tbi) (200 Cgy)/fludarabine (Flu) Nonmyeloablative conditioning for allogeneic stem cell transplants (alloSCT) (2000) (0)
[Immunosuppression and induction of tolerance by fractionated total lymphoid irradiation]. (1985) (0)
Induction of Anti-Cancer Effects by Targeting Alloreactive Intentionally Mismatched T Cells and NK Cells to Tumor Cells Using Bi-Specific Trifunctional Antibodies. (2006) (0)
Immunotherapy of lymphoma by cytokines and allogeneic cell therapy (1999) (0)
myeloid leukemia in mice and in cell cultures Antitumor effects of human recombinant interleukin-6 on acute (2011) (0)
The use of soybean agglutinin (SBA) for bone marrow (BM) purging and hematopoietic progenitor cell enrichment in clinical bone-marrow transplantation. (1999) (0)
Traitement ou prevention du diabete a l'aide de cannabidiol (2005) (0)
Lichenoid reaction in bone marrow transplants suffering from chronic GVHD is associated with HLA-DQW1 (1992) (0)
ASTA-Z 7557 impairs human natural killer (NK) cell activity. (1996) (0)
Demonstration and characterization of virus released by murine B cell leukemia cells (BCL1). (1984) (0)
Post transplant immunotherapy for prevention of relapse after autologous bmt for acute leukemia (1998) (0)
Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL (2016) (0)
Biological response modifiers as adjuncts to stem cell transplantation (2006) (0)
Use of halofuginone for the manufacture of a medicament for the prevention of neovascularization and for the treatment of malignant tumors (1996) (0)
Results of Allogeneic Hematopoietic Cell Transplantation in Persons with Fanconi Anemia and Pretransplant Cytogenetic Abnormalities, Myelodysplastic Syndrome, or Acute Leukemia (2011) (0)
Treatment of patients with metastatic solid tumors with intentionally mismatched lymphocytes activated with rIL-2 in the outpatient setting. (2004) (0)
Enhanced lymphoid cell recovery after bone marrow transplantation: correlation with the presence of costimulatory antibodies in serum. (1998) (0)
Thymoglobulin ® Rabbit Anti-Thymocyte Globulins (r-ATG) Induces Faster Platelet Recovery and Does Not Suppress Granulocyte Engraftment in a Non-Myeloablative Stem Cell Transplantation Setting. (2007) (0)
Bone marrow transplantation across major histocompatibility barriers: mechanisms and applications. Abstr. (1981) (0)
THE CANCER REVOLUTION Additional Material for Appendix 1 Prof . (2016) (0)
Proliferative response of murine B-cell leukemia (BCL1) to poly(L-lysine). (1985) (0)
The use of autologous mesenchymal stromal cells for treatment of neurodegenerative disorders - past achievements and future goals (2013) (0)
[Value of partial protection of lung tissue for prevention of radiation pneumonitis after total body irradiation]. (1991) (0)
The use of multi-potent mesenchymal stromal cells for control of inflammatory bowel disease (2018) (0)
2232 Radiation therapy has a positive inhibitory effect on the growth of fungal infection: In vitro and in vivo results (1999) (0)
Adoptive allogeneic cell-mediated immunotherapy and nonmyeloablative stem-cell transplantation (2000) (0)
Role of mesenchymal stem cells in delivering Newcastle disease virus to glioma cells and glioma stem cells and enhancing the oncolytic effect of the virus by secreting TRAIL. (2013) (0)
Potential elimination of multi-drug resistant cancer cells by targeted non-engrafting intentionally mismatched activated donor lymphocytes. (2019) (0)
Successful treatment of murine and rat experimental autoimmune encephalomyelitis with lidomide, a novel immunomodulator (1993) (0)
Long-Term Safety and Efficacy of Stem Cell Gene Therapy for ADA-SCID. (2006) (0)
IMMUNOSUPPRESSION AND PERMANENT TRANSPLANTATION TOLERANCE ACROSS MAJOR HISTOCOMPATIBILITY BARRIERS FOLLOWING TOTAL LYMPHOID IRRADIATION (1979) (0)
Transplant of ex vivo incubated bone marrow with rIL -7 for the enhancement of immuno-hematopoietic reconstitution (2015) (0)
disease induced by allogeneic lymphocytes Use of trifunctional bispecific antibodies to prevent graft-versus-host (2011) (0)
Is nonmyeloablative stem cell transplantation (Nst) Associated with increased risk of delayed hemolysis (2000) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Shimon Slavin?

Shimon Slavin is affiliated with the following schools:

Shimon Slavin's Academic­Influence.com Rankings

Shimon Slavin's Degrees

Why Is Shimon Slavin Influential?

Shimon Slavin's Published Works

Published Works

What Schools Are Affiliated With Shimon Slavin?

Shimon Slavin's AcademicInfluence.com Rankings